Introduction: There is compelling evidence that COPD increases CoViD-19 mortality. Several predictors of the outcome of COPD patients have been investigated but the role of baseline medications still remains unclear.

Aims and objectives: The aim of this study was to validate the excess risk conferred by COPD in a sample of CoViD-19 patients in Crete, Greece and to further investigate the possible effect of baseline COPD regiments on the outcome.

Methods: This is a retrospective observational study that included 776 CoViD-19 patients that presented for Emergency Room (ER) evaluation from March to August 2021, some of which were subsequently hospitalized. Univariate and multivariate logistic analyses were used to investigate the association of risk factors with death.

Results: The overall in hospital case fatality rate (CFR) was 5.54% [4.03%-7.39%] in a sample with a median age of 47 [30-65] years and comorbidities were identified for 68.8% of the participants. Only 8.89% of the participants were fully vaccinated. There were 66 (8.5%) recorded COPD patients. COPD patients were at higher risk of death with an aOR 1.65[0.74-3.67] adjusting for age, gender and vaccination status while history of COPD and a triple baseline regimen of LABA/LAMA/ICS was also associated with a significantly increased risk of death (aOR= 4.32[1.71-10.90])

Conclusions: CoViD -19 related deaths in COPD patients, especially those with comorbitities represented a higher mortality rate. A considerable portion of COPD patients receiving triple LABA/LAMA/ICS regimen that tested positive for CoViD-19 suffered a greater mortality rate. Further research is needed to evaluate this hypothesis.